Clinical Trial Update: Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating senicapoc in COVID-19 patients with severe respiratory insufficiency (ARDS).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Senicapoc (senicapoc)

Snippet

Sponsor: University of Aarhus | Conditions: ARDS, Human, COVID | Phase 2 | Status: UNKNOWN